Tuesday, 15 November 2011
Galenica has acquired all of the outstanding shares of Vifor Uriach Pharma SL, a joint venture with its Spanish partner Grupo Uriach, as well as Grupo Uriach’s Primary Care Business (dealing with medical practices). This will improve the ability of Galenica to commercialise the intravenous iron products Ferinject® and Venofer® as well as several in-licensed products. This acquisition is a further example of Galenica’s strategy to build a strong presence in key European markets and provides Vifor Pharma with additional sales capability in hospitals and medical practices in Spain.
_Vifor Uriach Pharma SL, a joint venture controlled by Galenica, was established in 2009 between Galenica and its longstanding local partner Grupo Uriach, to commercialise Vifor Pharma’s intravenous (i.v) iron products Ferinject® and Venofer®.
_Galenica has acquired all of the outstanding shares of the company and will rename it Vifor Pharma España SL. The Spanish venture of Galenica incorporates Vifor Uriach Pharma SL and Grupo Uriach’s Primary Care Business (dealing with medical practices) including their medical, marketing and sales organisation. The company is based in Barcelona and will help capitalise on the full market potential of Ferinject® by offering the product to a broader group of physicians and patients.
_Along with Ferinject® and Venofer®, Vifor Pharma España SL will commercialise a broad portfolio of well established products and several new innovative in-licensed products such as Copalia® (hypertension), Vimovo® (inflammation, pain management) and Alvesco® (asthma).
_The acquisition was effective on 14 November 2011. Financial terms of the agreement will not be disclosed.
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).
_Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).
_Vifor Pharma, a company of the Galenica Group, is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global presence and a broad network of affiliates and partners around the world.
Venofer® (iron sucrose injection) is the leading intravenous (i.v.) iron product for the treatment of iron deficiency anaemia in renal patients. Ferinject® (ferric carboxymaltose) is a novel i.v. iron replacement therapy, also a non-dextran iron that can be rapidly administered in large i.v. doses. Ferinject® is currently registered for use in 37 countries worldwide.
_For more information please visit the company’s website at www.viforpharma.com.
Thursday, 15 December 2011
Monday, 12 December 2011
Monday, 14 November 2011
Friday, 11 November 2011
Thursday, 13 October 2011
Head of Corporate Communications